Aim: Pharmacological treatments are often used in treating the behavioural and psychological symptoms of dementia (BPSD) in nursing homes, despite the fact that non-pharmacological treatments are recommended as a firstline treatment and can provide a suitable alternative. Because the course of BPSD is known to fluctuate depending on individual symptoms over time, the frequencies of drug use and BPSD, as well as their association, should be observed over a longer period. We investigated the association between the changes in psychotropic drug (PD) use and BPSD, focusing on the number of symptoms, severity, and care burden over 1 year among longterm care facility residents. Methods: A 1-year follow-up study was conducted among older residents with dementia or similar symptoms (n = 312 at baseline; n = 237 at followup) by using a care staff questionnaire in 10 long-term care facilities in Hokkaido, Japan. Medication use was determined based on prescription information. The brief questionnaire form of the Neuropsychiatric Inventory was used to assess BPSD. Results: Among residents followed up for 1 year, new users of PDparticularly anxiolytics and hypnotics-had a significantly increased number and severity of BPSD, compared with non-PD users. Continuing PDs was also related to increased severity over the year. Among residents with any persistent BPSD for 1 year, new use of PDs-particularly anxiolytics and hypnotics-was significantly associated with an increased care burden of BPSD, compared with the non-use of PDs. The discontinuation of PDs was significantly associated with a decreased care burden, compared with the non-use of PDs. Conclusions: Our study suggests that PDs, particularly anxiolytics and hypnotics, may be prescribed carefully in response to exacerbation of BPSD in terms of the number of symptoms, severity, and care burden in long-term care facilities. Continuous monitoring of PDs use and BPSD is important to effectively address BPSD.
INTRODUCTION
approaches include environmental, caregiver, and behavioural interventions. 4 Most treatments can be categorized as caregiver interventions, the mild but confirmed efficacy of which were recently recognized in a meta-analysis. 5 Pharmacological treatments, an alternative option for BPSD, should be used when non-pharmacological treatments are ineffective. 3 Psychotropic drugs (PDs), including antipsychotics, antidepressants, anxiolytics, and hypnotics, are commonly used in nursing homes. However, long-term use and over-use have become problems. [6] [7] [8] PD use increases dramatically after nursing home admission. 6 Additionally, nursing home residents are more likely to receive PDs continuously, despite the uncertain effects of the drugs on alleviating BPSD. 7 These suggest a need to review the use of routine medicines. 9 In addition, many studies have indicated that, compared with other PDs, antipsychotics and antidepressants are more frequently prescribed to people with BPSD in nursing homes. [10] [11] [12] Our previous cross-sectional study found an association between antipsychotics and the prevalence of specific BPSD (i.e. delusions, anxiety, and disinhibition) among older people with dementia or similar symptoms in longterm care facilities. 13 Although using antipsychotics for BPSD treatment is common, guidelines on dementia recommend the careful use of these drugs because of serious sideeffects. 3 However, recent studies of nursing home residents have found that the proper use of antipsychotics did not show negative effects. 14, 15 For example, a 2-year longitudinal study in nursing homes suggested that most PDs, including antipsychotics, did not reduce physical or cognitive function. 14 A 75-month longitudinal study among nursing home residents reported no association between antipsychotic use and mortality. 15 The risks and benefits associated with PDs are therefore controversial. Factors related to the prescription of PDs have been reported recently. One study demonstrated that in long-term care facilities, the use of antipsychotics was two to three times higher among elderly people with moderate-to-severe behavioural symptoms, than among patients without such symptoms. 16 Another study reported that severe cognitive impairment, dementia, and motor agitation were significantly associated with the new use of antipsychotics among long-term care facility residents. 17 Our previous cross-sectional study of long-term care facility residents indicated that the use of PDs was not associated with the prevalence of BPSD, but it was associated with a higher number of BPSD, as well as a greater severity and care burden of BPSD. 13 In contrast, a cross-sectional study among communitydwelling people with dementia found no association between the use of PDs and either behavioural disturbances or family caregiver burden. 18 Rather, it was the characteristics of the caregiver and care recipient that were significantly associated with the use of PDs. 18 Another study revealed that the care staff's perceptions of psychiatric morbidity were a stronger influence on the prescription of PDs than were the standardized clinical criteria. 19 These studies suggest that careful observation is needed to identify the factors related to PD prescription. Because the course of BPSD is known to fluctuate depending on individual symptoms over time, 7, 20 further research is required to determine the frequencies of PD use and BPSD, as well as their association, over a longer period. In the present 1-year longitudinal study, we investigated the relationship between changes in PD use status and changes in BPSD with respect to the number of symptoms, severity, and care burden over the year. The findings provide useful information for the review of PD prescription and BPSD.
METHODS

Design and participants
We conducted a 1-year prospective cohort study that followed older people with dementia or similar symptoms residing at 10 selected long-term care facilities in Hokkaido, Japan's northernmost prefecture. We selected these 10 facilities by using snowball sampling to increase cooperation and response rate.
Residents of these facilities considered to have dementia were included in the sample. To identify people with dementia, medical records for all residents were available, but residents with symptoms of dementia were not always diagnosed with dementia. Therefore, we used the 'screening judgement of the level of independence in daily life for the elderly with dementia', which was available for all residents. This measure was developed by the Japanese Ministry of Health, Labour and Welfare, 21 and it is the most common method for health practitioners and care workers in Japan to evaluate the disability of daily living with symptoms of dementia at eight levels of severity (none, I, IIa, IIb, IIIa, IIIb, IV, and M). Symptoms include declines in learning and memory, executive function, complex attention, perceptual-motor skills, and social cognition. The validity of the assessment measure was reported in a previous study in which the correlation coefficient with the Functional Assessment Staging of Alzheimer's Disease was demonstrated to be 0.684. 22, 23 At each facility, residents had been assessed regularly by experienced care staff. We considered those assessed at level I or higher to have dementia and included them in our study. The symptoms and conditions of each level were previously explained elsewhere. 13 We obtained informed consent from residents' family members at seven facilities and from the facility directors at three facilities. The details of these procedures were previously described elsewhere. 24 We excluded those who did not have dementia and those who moved out or were hospitalized before the study began. A total of 312 residents from 10 longterm care facilities were included in the study. They were assessed twice at an approximately 1-year interval based on a questionnaire for care staff (AprilNovember 2015 and September-December 2016). Full details of the baseline study were previously described elsewhere. 13 
Measures
The study questionnaire examined sociodemographic characteristics, health conditions including the underlying cause of dementia and medications, and BPSD. The care staff who generally cared for or were close to the participants completed the questionnaires while referencing medical and care records. The level of long-term care need included care stages 1 (low) to 5 (high). 24 The underlying cause of dementia was classified as Alzheimer's disease, vascular dementia, frontotemporal lobar degeneration, dementia with Lewy bodies/Parkinson's disease dementia, mixed dementia, other types of dementia, or dementia-like symptoms without a diagnosis. We were unable to determine the diagnostic criteria used, so we described the participants who were considered to have dementia as 'residents with dementia or similar symptoms'. Regarding medication, we classified each drug according to the Anatomical Therapeutic Chemical Classification System. 25 Based on a previous study, 26 PD use was defined as taking antipsychotics (Anatomical Therapeutic Chemical class N05A, excluding lithium), antidepressants (N06A), and anxiolytics and hypnotics (N05BA, N05BE, N05CD, N05CF, N05CH, and suvorexant). Antipsychotics were divided into conventional antipsychotics (N05AA-AD, N05AF, N05AG, and N05AL) and atypical antipsychotics (other drugs in N05A, excluding lithium). We also classified yokukansan, a Japanese herbal medicine originating from traditional Chinese medicine, as a PD. Yokukansan, which is used to treat neurosis, insomnia, and irritability and/or agitation in infants, has been reported as effective in improving BPSD in patients with dementia. 27 Activities of daily living (ADL) were evaluated by the Physical Self-Maintenance Scale, 28 which consists of six items regarding toileting, feeding, dressing, grooming, physical ambulation, and bathing, with a 5-point Guttman rating scale (1 to 5). Each item score was summed, providing total scores ranging from 6 to 30. A higher score indicated more dependence in ADL. The Japanese version of this scale has well-established interrater reliability. 29 The internal consistency of the six items in our baseline study, assessed by Cronbach's α coefficient, was 0.89. Cognitive function was assessed by a seven-item subscale of the Mental Function Impairment Scale, which has been demonstrated to have good validity and reliability. 30, 31 The subscale consists of items regarding orientation in space, orientation in time, recent memory, distant memory, discourse comprehension, indication of intention, and decision-making and is measured on a 7-point scale (0-6 points). All the item scores were summed, providing total scores ranging from 0 to 42. A higher score indicated more impaired cognitive functioning. In our baseline study, this subscale had a Cronbach's α coefficient of 0.97. The brief questionnaire form of the Neuropsychiatric Inventory, which is well validated for examining psychopathology in dementia, 32 was used to assess BPSD. The Japanese version of this assessment was developed by Matsumoto et al. 33 It consists of 12 items related to types of BPSD: delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviours, night-time disturbances, and appetite/eating disturbances. We queried each item with three options: yes, no, or not applicable for medical reasons. We further assessed the BPSD items regarding severity on a 4-point scale (0-3 points) and care burden on a 6-point scale (0-5 points). In this severity assessment, people who did not appear to have BPSD were rated as 0. Care burden was assessed only when people exhibited BPSD. The severity scores and care burden scores were summed across items, with total scores ranging from 0 to 36 for severity and 0 to 60 for care burden. Higher scores indicated greater severity or burden of care. Night-time disturbances and appetite/eating disturbances are generally not included in assessments of severity or care burden. However, both were included in the calculation of total severity and care burden in this study because they were considered important components of BPSD. The Cronbach's α values for severity at baseline and follow-up were 0.70 and 0.74, respectively. For care burden at baseline and follow-up among participants who were followed up and had persistent BPSD, the Cronbach's α values were 0.65 and 0.68, respectively. These findings indicate a high level of internal consistency reliability. The present study adhered to the Declaration of Helsinki and was approved by the Ethical Committee of the Hokkaido University Graduate School of Medicine.
Statistical analysis
We examined differences in participants' characteristics at baseline to compare them with those of participants who were and were not followed up; χ 2 tests were used for categorical variables and Welch's ttests for continuous variables. Medication was assessed over the year based on use rate, new use rate, continuation, and discontinuation. The use rate was defined as the proportion of residents prescribed drugs at baseline and at follow-up. The 1-year use rate was the proportion of residents with complete follow-up who had been prescribed drugs either at baseline or follow-up. The new use rate was the proportion of residents prescribed no drugs at baseline but who had been prescribed drugs by the follow-up. Among the residents who had been prescribed drugs at baseline, continuation was the proportion still prescribed any persistent drug at follow-up, and discontinuation was the proportion who were no longer prescribed any drugs at follow-up. We calculated the means AE SD of the differences in the number of BPSD and the BPSD severity and care burden scores for the sum of the 12 symptoms at baseline and follow-up according to PD medication status over 1 year (non-use, new use, continuation, or discontinuation). We used a generalized linear mixed-effects model to examine the associations between PD medication status over 1 year and BPSD changes in terms of the number of symptoms, severity score, and care burden score. In this model, repeated measures of BPSD variables (at baseline and follow-up) were used as the longitudinal outcome. These response variables were countable data with only a small variance from the mean; we therefore applied the Poisson distribution with a log-link function. A random intercept and a random slope for time were assumed, meaning that the model accounted for individual variation in the baseline response variables and variation in changes in the response variables over time. The model also included potential confounding factors such as sex, age group (<88 or ≥88 years, based on the median age), type of facility, underlying disease of dementia (Alzheimer's disease, vascular dementia, other, or not identified), level of long-term care need, baseline ADL function score (<15 or ≥15, based on the median for this score), baseline cognitive function score (<17 or ≥17, based on the median for this score), and the interaction between the baseline ADL and cognitive function scores. This interaction was found to be a BPSD-related factor in our previous study. 24 No over-dispersion was observed in the models. All calculations were performed using R version 3.2.3 (https://www.R-project.org/).
RESULTS
Participants' characteristics
As shown in Table 1 , 237 participants were followed up, and 75 were not because they had died, been hospitalized, or moved to other facilities. The mean follow-up period was 473 AE 32 days. Those who were not followed up were more likely to need longterm care and have impairments in ADL and cognitive function than those who were followed up. Except for these variables, no significant differences were observed between the two groups.
Psychotropic drug use at the 1-year follow-up Psychotropic drug use was examined among those who were followed up (n = 237). The mean number of PDs was 0.7 AE 1.0 (range: 0-4) at baseline and 0.8 AE 1.2 (range: 0-6) at follow-up. As shown in Table 2 , the PD use rate at baseline was 44.3%, and the 1-year use rate was 49.8%. The new use rates for all PDs were below 10%. The 1-year use rate of anxiolytics and hypnotics (30.8%) was the highest among PDs. Most drugs showed continuation rates over 70%, with antidepressants having the highest (89.5%) and yokukansan having the lowest (56.5%) continuation rate.
Relationship between changes in psychotropic drug status and changes in the number, severity, and care burden of behavioural and psychological symptoms of dementia over 1 year Among the participants who were followed up and had no missing data (n = 236), the new use of PDsespecially anxiolytics and hypnotics-was associated with an increased number of BPSD and increased severity of BPSD, compared with the non-use of PDs over 1 year, after potential confounding factors were controlled for (Table 3) . Additionally, those who continued to use PDs were more likely than with nonusers of these drugs to show increased severity of BPSD. Among the participants who persistently exhibited any BPSD at both baseline and follow-up (n = 119), the new use of PDs-especially anxiolytics and hypnotics-was related to an increased care burden of BPSD, compared with the non-use of these drugs over the year (Table 3) . Discontinuing PDs, compared with the non-use of these drugs, was associated with a decreased care burden of BPSD. Those who continued to use antidepressants tended to have a greater care burden of BPSD than non-users of these drugs, although this finding was not statistically significant (P = 0.051). Changes in the use of antipsychotics and yokukansan were not significantly associated with changes in BPSD.
DISCUSSION
We reported the longitudinal observation of the use of PDs and BPSD among residents with dementia or AD, Alzheimer's disease; ADL, activities of daily living.; BPSD, behavioural and psychological symptoms of dementia; VaD, vascular dementia. † χ 2 tests were performed to examine differences in the categorical variables between participants who were followed up and those who were not, and Welch's t-tests were performed to examine differences in the continuous variables. ‡ Other represents rare types of dementia such as frontotemporal lobar degeneration, dementia with Lewy bodies, and mixed-type dementia.
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© 2018 Japanese Psychogeriatric Society similar symptoms in long-term care facilities in Japan. The use rate of PDs reported in this study was low compared with rates in European countries, but this may be explained partly by different classifications of PDs. 13, 34 Another explanation is that the prevalence of BPSD was lower than in other countries. 24 We also showed that antidepressant and yokukansan use rates were relatively low, compared with use rates of anxiolytics and hypnotics and antipsychotics. In recent cross-sectional and longitudinal studies, the use of antidepressants, which were employed as frequently as antipsychotics, ranged from 17.1% to 41.1%. 10, 11, 34, 35 In Japan, a previous study of outpatients prescribed anticholinesterase drugs showed that the use of antidepressants was 13.0%-half of the antipsychotic use. 36 This corresponds with our results. The continuation rates of all PDs, except for yokukansan, were over 70%. This supports previous reports in other countries, which have shown rates of 89-91% for PDs and 72-85% for antipsychotics during 6-to 12-month intervals among residents with dementia in nursing homes and specialized care units. 7, 10, 35, 37 There have been several studies on factors related to the continuous use of PDs. One study demonstrated that more BPSD and longer periods of nursing home residence were associated with persistent use of PDs. 10 Our finding of increased BPSD severity associated with the continuation of PDs partly supported this previous study. Given yokukansan's low continuation rate and relatively high discontinuation rate, the drug may be easily used because of few adverse side-effects, 38 but it may frequently be discontinued because of a lack of efficacy for treating BPSD. Antidepressants had the highest continuation among all PDs in our study. This may reflect the high persistence rate of depression, which was 74% in our study, marking the highest rate among all 12 BPSD items (data not shown). The new use rate of all the PDs is below 10%, and this corresponds with findings in previous studies. 35, 39 Because the residents with high levels of long-term care need were less likely to be followed up in our study, those potentially requiring PDs might not have been included in the analyses. The characteristics of the participants could thus be related to the low new use rate of the drugs. However, the reason for this low rate is not clear from our study. We found that the new use and continuation of PDs over the follow-up period, compared with the non-use of these drugs, were significantly associated with an increased number of BPSD and an increased severity of BPSD among the residents who were followed up, after potential confounding factors were controlled for. Moreover, compared with non-users of PDs, new users of these drugs had an increased care burden of BPSD, and discontinuing PD use was associated with a decreased care burden of BPSD among those with any persistent BPSD over the year. These relationships were particularly strong for anxiolytics and hypnotics. This finding may result from PDs being newly prescribed when BPSD are thought to have worsened. Additionally, an increase in the severity of BPSD may impact the continued use of PDs, and a decreased care burden of BPSD may impact the discontinuation of PDs. It is suggested that the prescription of PDs might be carefully handled in response to the fluctuation of BPSD numbers, severity, and care burden. We did not detect an association between changes in specific categories of PDs, such as antipsychotics, antidepressants, or yokukansan, and changes in BPSD, except for anxiolytics and hypnotics. This may be partly because of the small sample size and short follow-up period. Although benzodiazepines, which are used as anxiolytics and hypnotics, are suspected to be a risk factor for adverse drug reactions commonly observed among those of older ages, 40 this was not a clear finding in our study. A meta-analysis of the discontinuation of antipsychotics in patients with dementia showed that the change in BPSD severity did not significantly differ between patients who stopped using the drugs and those who continued to use them, although patients with more severe BPSD tended to be in the discontinuation group. 41 A study that considered the factors regarding PD use found that nurses and general practitioners in nursing homes tended to have a low willingness to discontinue antipsychotics because of barriers such as concerns about negatively affecting residents' quality of life and the recurrence of BPSD. 42 Furthermore, organizational factors in nursing homes such as the number of physicians and physicians' perceived beliefs about the positive effects of drugs for patients and care staff could influence the use of antipsychotics. 43, 44 In addition to these studies on antipsychotic use, the qualitative study by Smeets et al. developed a conceptual framework for factors related to PD prescription in nursing homes, including physicians' and nurses' perceptions, knowledge of PDs and their side-effects, decision-making on PD use and withdrawal, and national and local policies. 45 Multiple factors besides BPSD status could influence medication with PDs. These factors should regularly be given more attention in the review of PD effectiveness. This study had several limitations. Participants were lost to follow-up mainly because of hospitalization or death. It is possible that those with severe BPSD may have been excluded from our study. Additionally, the facilities in our study were not randomly selected, and our sample was relatively small. Therefore, our sample may not represent the general population of care facility residents with dementia. Ideally, every individual should be clinically diagnosed, but this was not possible in the facilities we observed. Consequently, some participants may have been incorrectly classified, which could bias the results. It is possible that the study population may have included patients with other psychiatric disorders, which could influence the prescription of psychotropic drugs. The presence of BPSD was assessed by care staff close to the participating residents, including care workers, nurses, and social workers. This variety of job types and subjective evaluation could result in an underestimation or overestimation of the frequency of BPSD. However, during the baseline study, we confirmed that there were no differences in BPSD prevalence related to the care staff's sex, age, job type, or duration of care experience. We could not control for interactions between drugs. Finally, other possible confounding factors that were not controlled in our study could bias the results.
Despite these limitations, this is one of the few studies describing PD use in association with BPSD number, severity, and care burden among residents, drawing on longitudinal observation in long-term care facilities in Japan. Our findings from the 1-year observation suggest that PDs-especially anxiolytics and hypnotics-might be prescribed in response to changes in BPSD number, severity, and care burden. Moreover, the effectiveness of some PDs, such as antipsychotics, antidepressants, and yokukansan, should be carefully reviewed, although their use rates were relatively low in this study. Further investigations of PD use and its associations with BPSD over longer follow-up periods are needed, and updated information on pharmacological approaches is important for effectively addressing BPSD.
